56
Participants
Start Date
December 31, 2005
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2010
dexamethasone
20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
thalidomide
100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
zoledronic acid
4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Singapore General Hospital, Singapore
National Cancer Centre, Singapore, Singapore
Gleneagles Hospital, Singapore, Singapore
Tan Tock Seng Hospital, Singapore, Singapore
Christian Medical College, Vellore
Tata Memorial Hospital, Mumbai
Chonnam National University Hwasun Hospital, Gwangju
Seoul National University Hospital, Seoul
Samsung Medical Center, Seoul, South Korea, Seoul
ASAN Medical Center, University of Ulsan, South Korea, Seoul
Collaborators (1)
Singapore General Hospital
OTHER
National Cancer Centre, Singapore
OTHER
Tan Tock Seng Hospital
OTHER
Seoul National University Hospital
OTHER
Asan Medical Center
OTHER
Samsung Medical Center
OTHER
Chonnam National University Hospital
OTHER
Christian Medical College, Vellore, India
OTHER
Tata Memorial Hospital
OTHER_GOV
Gleneagles Hospital
OTHER